Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 22, 2023 17:25 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Announces Notification of NYSE American Continued Listing Deficiency

BEDMINSTER, N.J., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small...
September 06, 2023 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Participate in the H.C. Wainwright Global Investment Conference

BEDMINSTER, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular...
August 22, 2023 07:30 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases

BEDMINSTER, N.J., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid...
August 09, 2023 16:05 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Reports Second Quarter 2023 Financial Results and Provides a Business Update

FDA indicated that approval of MAT2203 as a first-line treatment for invasive aspergillosis will require an adequately powered study with an active control group and an all-cause mortality...
August 02, 2023 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Participate in the BTIG Virtual Biotechnology Conference 2023

BEDMINSTER, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular...
July 26, 2023 08:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2023 Financial Results and Provide a Business Update on August 9, 2023

BEDMINSTER, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the...
May 11, 2023 07:30 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023

BEDMINSTER, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid...
May 10, 2023 16:05 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Reports First Quarter 2023 Financial Results and Provides a Business Update

FDA feedback from Type B meeting reiterated the Agency’s intent to work collaboratively in advancing development of MAT2203 for the treatment of invasive fungal infections (IFIs) Phase 3 trial design...
May 03, 2023 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023

BEDMINSTER, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery...
April 18, 2023 08:00 ET | Source: Matinas BioPharma Holdings, Inc.

Compassionate Use Patient Treated with Matinas BioPharma’s MAT2203 and Showing Complete Clinical Resolution of Rare R. mucilaginosa Fungal Infection Featured in Oral Presentation at ECCMID

BEDMINSTER, N.J., April 18, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right